Circulating lncRNA DRAIC as a Potential Serum Biomarker for Predicting Lymphatic and Vascular Spread in Pancreatic Cancer

Serum DRAIC as a Biomarker in PC

  • Ying Che Beijing Anzhen Hospital Affiliated to Capital Medical University
  • Ting Zhang Zhongshan Hospital, Fudan University
  • Jing Li Zhongshan Hospital, Fudan University
  • Xiao Jiang Zhongshan Hospital, Fudan University
  • Chao Li Beijing Anzhen Hospital Affiliated to Capital Medical University
  • Wei Li Beijing Anzhen Hospital Affiliated to Capital Medical University
DOI: https://doi.org/10.5937/jomb0-63713
Keywords: Pancreatic cancer, DRAIC, vascular involvement, lymph node metastasis, receiver operating characteristic curve

Abstract


Background: Pancreatic cancer is notorious for its aggressive behavior and poor prognosis, largely due to delayed diagnosis and early dissemination. Identifying reliable serum biomarkers could enhance early detection and risk stratification. Long non-coding RNAs (lncRNAs) have been recognized as regulators of tumor biology, however, the clinical and biochemical relevance of lncRNA DRAIC in pancreatic cancer has not been fully elucidated.

Methods: Serum samples were obtained from 100 patients diagnosed with pathologically confirmed pancreatic cancer and 100 age- and sex-matched controls. Quantitative real-time polymerase chain reaction (qPCR) was employed to quantify the circulating DRAIC expression levels. We analyzed the associations between serum DRAIC levels and clinicopathological characteristics, including vascular involvement and lymph node metastasis. Receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic and predictive performance of DRAIC. Paired serum samples obtained before and after surgical resection were additionally analyzed.

Results: Serum DRAIC expression was significantly elevated in patients with pancreatic cancer compared with controls. ROC analysis demonstrated robust diagnostic potential (AUC = 0.943). Elevated DRAIC levels were significantly associated with lymph node metastasis and vascular involvement. DRAIC showed strong predictive performance for lymph node metastasis (AUC = 0.906), whereas its predictive value for vascular involvement was moderate. Notably, serum DRAIC levels were significantly reduced following surgical resection.

Conclusion: Circulating lncRNA DRAIC is markedly dysregulated in pancreatic cancer and demonstrates potential utility as a serum-based biochemical biomarker, particularly for evaluating lymph node metastasis. These findings provide a basis for further mechanistic studies and validation in larger cohorts.

References

1. Yu C, Chen S, Guo Y, Sun C. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway. Theranostics 2018; 8(12): 3224-36.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
3. Zhang Q, Chen S, Zeng L, Chen Y, Lian G, Qian C, et al. New developments in the early diagnosis of pancreatic cancer. Expert Rev Gastroent 2017; 11(2): 149-56.
4. Ilmer M, Boiles AR, Regel I, Yokoi K, Michalski CW, Wistuba II, et al. RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. Cancer Res 2015; 75(9): 1883-96.
5. Deplanque G, Demartines N. Pancreatic cancer: are more chemotherapy and surgery needed? Lancet (London, England) 2017; 389(10073): 985-6.
6. Li Y, Chen H, Pan T, Jiang C, Zhao Z, Wang Z, et al. LncRNA ontology: inferring lncRNA functions based on chromatin states and expression patterns. Oncotarget 2015; 6(37): 39793-805.
7. Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, et al. Long Noncoding RNA MALAT1 Regulates Cancer Glucose Metabolism by Enhancing mTOR-Mediated Translation of TCF7L2. Cancer Res 2019; 79(10): 2480-93.
8. Zheng Z, Chen M, Xing P, Yan X, Xie B. Increased Expression of Exosomal AGAP2-AS1 (AGAP2 Antisense RNA 1) In Breast Cancer Cells Inhibits Trastuzumab-Induced Cell Cytotoxicity. Med Sci Monitor 2019; 25(2211-20.
9. Wang J, Sun J, Wang J, Song Y, Gao P, Shi J, et al. Long noncoding RNAs in gastric cancer: functions and clinical applications. Oncotargets Ther 2016; 9(681-97.
10. Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. Chemmedchem 2014; 9(9): 1932-56.
11. Mitobe Y, Takayama K, Horie-Inoue K, Inoue S. Prostate cancer-associated lncRNAs. Cancer Lett 2018; 418(159-66.
12. Fang X, Pan H, Leng R, Ye D. Long noncoding RNAs: novel insights into gastric cancer. Cancer Lett 2015; 356(2 Pt B): 357-66.
13. Liu Y, Zhang R, Ying K. Long non‑coding RNAs: novel links in respiratory diseases (review). Mol Med Rep 2015; 11(6): 4025-31.
14. Tian X, Xu G. Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis. Bmj Open 2015; 5(9): e008653.
15. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010; 38(16): 5366-83.
16. Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, et al. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer 2011; 10(141.
17. Sakurai K, Reon BJ, Anaya J, Dutta A. The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus. Molecular Cancer Research : MCR 2015; 13(5): 828-38.
18. Sun M, Gadad SS, Kim D, Kraus WL. Discovery, Annotation, and Functional Analysis of Long Noncoding RNAs Controlling Cell-Cycle Gene Expression and Proliferation in Breast Cancer Cells. Mol Cell 2015; 59(4): 698-711.
19. Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut 2015; 64(9): 1476-84.
20. Collins DC, Morris PG. Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opin Pharmaco 2015; 16(6): 851-61.
21. Yang J, Hu Z, Shi W, Deng T, He S, Yuan S. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroentero 2015; 21(9): 2807-15.
22. Wu G, Pan H, Leng R, Wang D, Li X, Li X, et al. Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun Rev 2015; 14(9): 798-805.
23. Gan L, Xu M, Zhang Y, Zhang X, Guo W. Focusing on long noncoding RNA dysregulation in gastric cancer. Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine 2015; 36(1): 129-41.
24. Chujo T, Yamazaki T, Hirose T. Architectural RNAs (arcRNAs): A class of long noncoding RNAs that function as the scaffold of nuclear bodies. Biochimica Et Biophysica Acta 2016; 1859(1): 139-46.
25. Bassett AR, Akhtar A, Barlow DP, Bird AP, Brockdorff N, Duboule D, et al. Considerations when investigating lncRNA function in vivo. Elife 2014; 3(e03058.
26. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136(4): 629-41.
27. Louro R, Smirnova AS, Verjovski-Almeida S. Long intronic noncoding RNA transcription: expression noise or expression choice? Genomics 2009; 93(4): 291-8.
28. Yang F, Zhang L, Huo X, Yuan J, Xu D, Yuan S, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (Baltimore, Md.) 2011; 54(5): 1679-89.
29. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013; 32(13): 1616-25.
30. Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng X, et al. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res 2013; 354(3): 891-6.
31. Li S, Li B, Zheng Y, Li M, Shi L, Pu X. Exploring functions of long noncoding RNAs across multiple cancers through co-expression network. Sci Rep-Uk 2017; 7(1): 754.
32. Tiessen I, Abildgaard MH, Lubas M, Gylling HM, Steinhauer C, Pietras EJ, et al. A high-throughput screen identifies the long non-coding RNA DRAIC as a regulator of autophagy. Oncogene 2019; 38(26): 5127-41.
Published
2026/03/05
Issue
Ahead of print
Section
Original paper

Copyright (c) 2026 Ying Che, Ting Zhang, Jing Li, Xiao Jiang, Chao Li, Wei Li

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.